Scientists hunt for genetic and environmental clues in rare lung disease
NCT ID NCT04238871
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to describe the features and natural history of idiopathic interstitial pneumopathy, a group of rare lung diseases, in both children and adults. Researchers planned to collect data from 1,600 participants, including medical history, imaging, and genetic tests, to understand how the disease starts and progresses. The study was terminated early, so results may be limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could improve understanding of how these rare lung diseases develop and progress, potentially guiding future research toward better diagnosis or management.
- What could go wrong
- This is an observational study that was terminated early, so it may not provide complete data. It does not test any treatment, so direct patient benefits are unlikely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,600 people
The number who actually took part.
- Started
-
Jun 2017
- Finished
-
Jan 2022
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patient with a diagnosis of Pneumopathie Interstitielle Diffuse/ Idiopathic Interstitial Pneumonia diagnosis is established on presenting history, clinical, radiological and functional and if available pathological findings.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest * Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing * Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise * Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol * Patients affiliated to the "Regime National d'Assurance Maladie" Exclusion Criteria: * Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders * Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Idiopathic interstitial pneumopathy/pneumopathy interstitial diffuse are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AP-HP - Hôpital Armand Trousseau
Paris, 75012, France
-
CHU Lyon - Hôpital Louis Pradel
Bron, 69500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.